Business Wire

W&W Group Deepens Partnership with Regnology to Future-Proof Regulatory Reporting Infrastructure

8.10.2025 09:59:00 CEST | Business Wire | Press Release

Share

Regnology, a global leading software provider of regulatory reporting and supervisory technology solutions, is proud to announce that its client, W&W Group, a prominent German financial services provider, is migrating its on-premise deployment of Regnology’s regulatory reporting solution to the Regnology Reporting Hub (RRH)—a cloud-native banking platform hosted on Rcloud, Regnology’s secure and scalable hyperscale-grade cloud infrastructure. This pivotal transition elevates W&W Group’s agility and resilience.

Headquartered in Kornwestheim, W&W Group provides home financing, insurance, and wealth management services, with total assets of €72.3 billion as of 31 December 2024. Since 2011, the institution has relied on Regnology to manage regulatory and capital market transaction reporting across its banking, insurance, and asset management entities. With the transition to Rcloud-hosted RRH, W&W Group gains access to elastic scalability, robust security, and efficient processing of large regulatory datasets. Rcloud also provides managed services such as batch processing, platform oversight, and continuous updates aligned with regulatory changes.

This strategic migration marks a key milestone in W&W Group’s digital transformation journey, delivering future-proof infrastructure to support long-term growth. W&W Group leverages RRH’s comprehensive coverage across banking regulations—including own funds, liquidity, statistical, Pillar 3 disclosure, deposit insurance, SRB, FinRep, AnaCredit, and transaction-level regimes such as EMIR, MiFIR, SFTR, and MMSR—ensuring compliance across jurisdictions.

Maciej Piechocki, Chief Revenue Officer of Regnology, commented: "We’re proud to support W&W Group’s transformation with best-in-class technologies and modern architecture. Our RRH platform on Rcloud empowers institutions to meet regulatory demands with speed, security, and confidence. This future-ready solution delivers efficiency and scalability needed to navigate evolving industry requirements. We value our partnership with W&W Group and remain committed to supporting their strategic goals and the broader German financial community."

Bernd Groß, Head of Application Development Regulatory Reporting of W&W Group, said: "Partnering with Regnology is crucial for the digital transformation of regulatory reporting. As regulatory complexity and associated technology demands grow, we’re building a resilient, agile, and reliable reporting infrastructure. Regnology’s broad regulatory coverage, deep expertise, and long-standing collaboration make them a trusted partner."

In 2023, Regnology announced its strategic shift to hyperscale-cloud delivery of its industry-leading banking regulatory and tax reporting solutions introducing Rcloud powered by Google Cloud. Today, over 50% of Regnology’s clients have successfully transitioned to the cloud infrastructure and its related managed services across the world, supported by a network of 12+ data centres located in EMEA, APAC, and the Americas. This momentum reflects the industry’s drive toward superior operational efficiency, enhanced resilience, and readiness for AI-driven innovation. Client adoption is projected to reach 80% by Q2 2026.

AboutW&W Group

The W&W Group came into existence in 1999 as a result of the merger of the two long-standing companies Wüstenrot and Württembergische. Today, it develops and provides the four components of modern financial planning: financial security, residential property ownership, risk protection and savings and investment. It combines the Housing and Insurance divisions with the digital initiatives and brands of the group such as Adam Riese, which enables it to offer every customer the financial planning solution that suits them best. In doing so, the W&W Group focuses on omni-channel sales, ranging from its own mobile sales force to cooperation partners and sales agents, broker activities and digital initiatives. Today, approximately 13,000 people work as in-house staff or in the mobile sales force for the listed group headquartered in Kornwestheim, Germany.

About Regnology

Regnology is a leading technology firm on a mission to enhance efficiency, transparency, and stability in the financial markets. Regnology has a focus on regulatory reporting with thousands of financial institutions and corporates of all sizes, and close to 100 regulators and tax authorities as clients. Regnology connects regulators and regulated financial institutions across the world through purpose-built solutions and common standards, bringing greater data quality and cost savings to all. With over 1,200 employees in 25 countries and a fast, flexible, and future-proof platform, clients can quickly implement and derive value from Regnology’s solutions and rely on us to easily keep pace with ongoing regulatory changes.

Regnology was formed in 2021 when BearingPoint RegTech, a former business unit of BearingPoint Group, joined forces with Vizor Software, a global leader in regulatory and supervisory technology.

For more information about Regnology, connect with us on LinkedIn and X.

Visit our website: www.regnology.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008487821/en/

Contacts

Press Contact
Mireille Adebiyi – Chief Marketing Officer, Regnology
mireille.adebiyi@regnology.net

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye